Compare ASTRAZENECA PHARMA with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs UNICHEM LAB - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA UNICHEM LAB ASTRAZENECA PHARMA/
UNICHEM LAB
 
P/E (TTM) x 142.0 -47.7 - View Chart
P/BV x 43.5 1.2 3,711.9% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 ASTRAZENECA PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
UNICHEM LAB
Mar-19
ASTRAZENECA PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,278292 437.7%   
Low Rs883182 484.9%   
Sales per share (Unadj.) Rs228.4167.7 136.2%  
Earnings per share (Unadj.) Rs10.4-3.6 -285.5%  
Cash flow per share (Unadj.) Rs16.35.9 273.7%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs98.8372.3 26.5%  
Shares outstanding (eoy) m25.0070.38 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.4 334.6%   
Avg P/E ratio x104.2-65.3 -159.7%  
P/CF ratio (eoy) x66.439.9 166.6%  
Price / Book Value ratio x10.90.6 1,717.9%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m27,00816,680 161.9%   
No. of employees `0001.42.6 52.1%   
Total wages/salary Rs m1,5352,393 64.2%   
Avg. sales/employee Rs Th4,210.94,535.2 92.9%   
Avg. wages/employee Rs Th1,132.2919.8 123.1%   
Avg. net profit/employee Rs Th191.1-98.2 -194.6%   
INCOME DATA
Net Sales Rs m5,71011,801 48.4%  
Other income Rs m123984 12.4%   
Total revenues Rs m5,83312,785 45.6%   
Gross profit Rs m463-835 -55.4%  
Depreciation Rs m147674 21.9%   
Interest Rs m075 0.0%   
Profit before tax Rs m438-600 -73.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-343 -52.1%   
Profit after tax Rs m259-256 -101.4%  
Gross profit margin %8.1-7.1 -114.6%  
Effective tax rate %40.857.3 71.3%   
Net profit margin %4.5-2.2 -209.6%  
BALANCE SHEET DATA
Current assets Rs m3,20920,384 15.7%   
Current liabilities Rs m2,0705,029 41.1%   
Net working cap to sales %20.0130.1 15.3%  
Current ratio x1.64.1 38.3%  
Inventory Days Days72105 69.0%  
Debtors Days Days35135 25.9%  
Net fixed assets Rs m7909,023 8.8%   
Share capital Rs m50141 35.5%   
"Free" reserves Rs m2,41926,058 9.3%   
Net worth Rs m2,46926,199 9.4%   
Long term debt Rs m00-   
Total assets Rs m4,60531,496 14.6%  
Interest coverage xNM-7.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.4 330.9%   
Return on assets %5.6-0.6 -982.6%  
Return on equity %10.5-1.0 -1,075.8%  
Return on capital %17.7-2.0 -887.2%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3008,188 3.7%   
Fx outflow Rs m2,015596 338.1%   
Net fx Rs m-1,7157,592 -22.6%   
CASH FLOW
From Operations Rs m88-3,278 -2.7%  
From Investments Rs m-94-2,860 3.3%  
From Financial Activity Rs mNA-24 0.0%  
Net Cashflow Rs m-6-4,690 0.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 15.7 3.0 523.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   12,856 20,176 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

MEGHMANI ORGANICS Share Price Up by 11%; BSE 500 Index Up 0.2% (Market Updates)

Apr 22, 2021 | Updated on Apr 22, 2021

MEGHMANI ORGANICS share price is trading up by 11% and its current market price is Rs 126. The BSE 500 is up by 0.2%. The top gainers in the BSE 500 Index are MEGHMANI ORGANICS (up 10.9%) and ASTRAZENECA PHARMA (up 11.6%). The top losers are BEML and RITES .

SHILPA MEDICARE Share Price Up by 9%; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Apr 22, 2021 | Updated on Apr 22, 2021

SHILPA MEDICARE share price is trading up by 9% and its current market price is Rs 457. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 8.6%) and ASTRAZENECA PHARMA (up 10.2%). The top losers are GRANULES INDIA (down 0.4%) and CIPLA (down 0.5%).

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 22, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS